1C84 Sato, Takami - Thomas Jefferson University - Thomas Jefferson University
Dr. Sato

Takami Sato, MD, Ph.D

Contact Dr. Sato

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography
  2. Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization
  3. Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells
  4. Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma
  5. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases
  6. Biology of advanced uveal melanoma and next steps for clinical therapeutics
  7. Treatment strategies for clinically detectable metastatic uveal melanoma
  8. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth
  9. Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity
  10. Early arterial stasis during resin-based yttrium-90 radioembolization: Incidence and preliminary outcomes
  11. Tumor necrosis factor-α blockade and development of uveal melanoma: Expected adverse effect or just coincidence?
  12. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma 0CC6 : A randomized clinical trial
  13. High-dose vincristine sulfate liposome injection (Marqibo) is not associated with clinically meaningful hematologic toxicity
  14. The potential role of sunitinib targeting melanomas
  15. Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma
  16. A pilot study of sunitinib malate in patients with metastatic uveal melanoma
  17. Uveal melanoma trapped in the temple of doom
  18. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma
  19. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma
  20. Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy